Table of Contents
Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA
Angiogenesis and Antiangiogenesis Agents
Apoptosis, Necrosis, and Autophagy
Bioinformatics
Biomarkers
Cancer Stem Cells
Cell Cycle Regulators
Cellular Responses to Therapy
Chemoprevention
Clinical Trials
DNA Repair and Modulation
Drug Resistance and Modifiers
EGFR/Her2
Epigenetic Regulation of Tumor Immunity
Epigenetic Targets
Genomics, Proteomics, and Target Discovery
Hormonal Agents and Therapy
Immune Checkpoints
Immune Mechanisms Invoked by Radiation Therapy
Immune Modulators
Immune Monitoring / Clinical Correlates
Immune Response to Therapies
In Vitro and In Vivo Models for Targets
Molecular Classification of Tumors
Monoclonal Antibodies
mTOR/PI3-Kinase
Natural Products
New Molecular Targets
Novel Assay Technology
Pediatric-Early Drug Development
Pharmacogenetics, Pharmacogenomics, and Therapeutic Response
Pharmacokinetics and Pharmacodynamics
Protein-Protein Interaction
Radiotherapeutics
RNA and RNA-Based Technologies and Therapies
Signal Transduction Modulators
Target Identification and Validation
Therapeutic Agents: Biological
Therapeutic Agents: Small-Molecule Kinase Inhibitors
Therapeutic Agents: Other Topics
Topoisomerase Inhibitors
Tubulin-Interacting Agents
Tumor Immunology Targets
Tumor Microenvironment
Tumor Suppressors
January 2018
Volume 17, Issue 1 Supplement
Volume 17, Issue 1 Supplement
Jump to
- Angiogenesis and Antiangiogenesis Agents
- Animal Models
- Apoptosis, Necrosis, and Autophagy
- Bioinformatics
- Biomarkers
- Cancer Stem Cells
- Cell Cycle Regulators
- Cellular Responses to Therapy
- Chemistry
- Chemoprevention
- Clinical Trials
- DNA Repair and Modulation
- Drug Delivery
- Drug Design
- Drug Resistance and Modifiers
- Drug Screening
- EGFR/Her2
- Epigenetic Regulation of Tumor Immunity
- Epigenetic Targets
- Genomics, Proteomics, and Target Discovery
- Hormonal Agents and Therapy
- Immune Checkpoints
- Immune Mechanisms Invoked by Radiation Therapy
- Immune Modulators
- Immune Monitoring / Clinical Correlates
- Immune Response to Therapies
- In Vitro and In Vivo Models for Targets
- MAPK Pathways
- Metabolism
- Metastasis and Invasion
- Molecular Classification of Tumors
- Monoclonal Antibodies
- mTOR/PI3-Kinase
- Natural Products
- New Molecular Targets
- Novel Assay Technology
- Pediatric-Early Drug Development
- Pharmacogenetics, Pharmacogenomics, and Therapeutic Response
- Pharmacokinetics and Pharmacodynamics
- Protein-Protein Interaction
- Radiotherapeutics
- RNA and RNA-Based Technologies and Therapies
- Signal Transduction Modulators
- Target Identification and Validation
- Therapeutic Agents: Biological
- Therapeutic Agents: Small-Molecule Kinase Inhibitors
- Therapeutic Agents: Other Topics
- Topoisomerase Inhibitors
- Toxicology
- Tubulin-Interacting Agents
- Tumor Immunology Targets
- Tumor Microenvironment
- Tumor Suppressors
- Other Topics
Advertisement
